<DOC>
	<DOCNO>NCT02882113</DOCNO>
	<brief_summary>This study multicenter , single-arm , open-label , 24 week , investigator-initiated clinical trial ass influence CYP3A5 polymorphism liver function abnormality trough level change conversion Advagraf® liver transplant recipient .</brief_summary>
	<brief_title>Influence CYP3A5 Polymorphism Liver Function Abnormality Trough Level Change After Conversion</brief_title>
	<detailed_description>All subject liver transplant recipient take Tacrolimus bid adaptable register study classify expressive non-expressive CYP3A5 polymorphism genotype Advagraf® administer dose Tacrolimus bid der day 24 week . All subject check whether register hospital base CYP3A5 polymorphism genotype screen visit . Registered subject visit seven time hospital study include screen visit adverse reaction , acute rejection , trough level tested period . Subjects additionally agree PK study hospitalize state Tacrolimus bid therapy one day ago take IP . On first day hospitalization , his/her blood collect . At week 1 ( plus seven day ) conversion Advagraf® , his/her blood collect PK analysis .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>19 year old . Patients previously receive liver transplant last six month within last three year . Patients Tacrolimus immunosuppressive therapy twice day least two week . During Tacrolimus immunosuppressive therapy twice day least two week , patient follow condition . Patients normal liver function renal function . Patients monitor without complication acute rejection . Patients willing sign his/her consent . Patients Tacrolimus trough level result 2 ng/mg baseline . Patients steroid therapy due positive result acute rejection test baseline . Patients receive transplant besides liver . Patients allergic IP macrolide compound . Patients cyclosporine , bosentan , potassium spar diuretic . Patients genetic disease galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . Pregnant lactating woman . Patients willing adhere study procedures/treatments .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>